A Drug compliance overview and recontrol of Prolanis participants with diabetes mellitus and hypertension at the Bailang Public Health Centre in Manado City
Keywords:
Drug compliance, Recontrol, Prolanis, Diabetes mellitus, Hypertension, Bailang Health Center, Manado CityAbstract
Background: Non-communicable diseases cause the most deaths worldwide. In 2024, Manado City had 11,677 cases of diabetes mellitus (DM) and 43,368 cases of hypertension. Adherence to treatment is an indicator of successful disease management, but national research found that drug compliance and recontrol for DM and hypertension patients remain low. The control and management of diabetes and hypertension are the main focus of Prolanis, but some studies on Prolanis have found high levels of non-compliance, so researchers examined drug compliance and recontrol.
Aim: To provide an overview of a drug compliance and recontrol of Prolanis participants with DM and hypertension at the Bailang Public Health Center in Manado City.
Methods: Descriptive quantitative approach and a cross-sectional design involving 41 Prolanis DM and 55 Prolanis hypertension at the Bailang Public Health Center in Manado City. The questionnaire used is the SKI 2023.
Results: Prolanis DM participants found that 29 people (90.6%) demonstrated drug compliance as directed by their doctor, while 3 people (9.4%) were non-compliant. A total of 31 people (96.9%) attended recontrol regularly, while 1 person (3.1%) attended only occasionally. Prolanis participants with hypertension found that 50 people (90.9%) demonstrated regular drug compliance, while 5 people (9.1%) took their medication irregularly. A total of 51 people (92.7%) attended recontrol regularly, whereas 4 participants (7.3%) did so only occasionally.
Conclusion: Prolanis participants with DM and hypertension at the Bailang Public Health Center in Manado City were categorized as compliant with drug therapy and regular in recontrol as directed by their doctor.
References
1. Uthman OA, Ayorinde A, Oyebode O, Sartori J, Gill P, Lilford RJ. Global prevalence and trends in hypertension and type 2 diabetes mellitus among slum residents: a systematic review and meta-analysis. BMJ Open. 2022;12(e052393). doi:10.1136/bmjopen-2021-052393
2. Singh N, Shukla SK, John P, Bajpai R, Chugh P, Sengupta R, et al. Unveiling the twin epidemics of hypertension and diabetes: a cross-sectional analysis of sex-specific prevalence, risk, and hotspots in India’s epidemiological transition zones. BMC Public Health. 2025;25:1734. doi:10.1186/s12889-025-22983-y
3. Magliano DJ, Boyko EJ, Genitsaridi I, Piemonte L, Riley P, Salpea P, eds. IDF Diabetes Atlas. International Diabetes Federation. 2025. Accessed August 1, 2025. https://diabetesatlas.org/media/uploads/sites/3/2025/04/IDF_Atlas_11th_Edition_2025.pdf
4. Global report on hypertension: the race against a silent killer. World Health Organization. September 19, 2023. Acessed August 1, 2025. https://www.who.int/publications/i/item/9789240081062
5. Zahro ML, Sunanto S, Rahmat NN. Hubungan efikasi diri dengan kekambuhan pada pasien hipertensi di Posbindu Desa Senduro di wilayah UPT. Puskesmas Senduro. J Keperawatan. 2024;18(1):99–108. doi: 10.56586/jk.v18i1.397
6. Diabetes in Western Pacific - 2024. International Diabetes Federation. 2025. Accessed August 1, 2025. https://diabetesatlas.org/media/uploads/sites/3/2025/04/IDF_Atlas_11th_Edition_2025_WP_Factsheet.pdf
7. Survei Kesehatan Indonesia (SKI) dalam angka. Badan Kebijakan Pembangunan Kesehatan, Kementerian Kesehatan Republik Indonesia. 2023. Accessed August 11, 2025. https://drive.google.com/file/d/1rjNDG_f8xG6-Y9wmhJUnXhJ-vUFevVJC/view
8. Flood D, Edwards EW, Giovannini D, et al. Integrating hypertension and diabetes management in primary health care settings: HEARTS as a tool. Pan Am J Public Health. 2022;46:e150. doi: 10.26633/RPSP.2022.150
9. Govindani R, Sharma A, Patel N, Baradia P, Agrawal A. Assessment of medication adherence among patients with hypertension and diabetes mellitus in a tertiary healthcare center: a descriptive study. Cureus. 2024;16(6):e63126. doi:10.7759/cureus.63126
10. Thummak S, Uppor W, Wannarit LO. Patient compliance: a concept analysis. Belitung Nurs J. 2023;9(5):421–7. doi:10.33546/bnj.2807
11. Prevalensi, dampak, serta upaya pengendalian hipertensi dan diabetes di Indonesia. Badan Kebijakan Pembangunan Kesehatan, Kementerian Kesehatan Republik Indonesia. 2024. Accessed August 11, 2025. https://drive.google.com/file/d/1RGiLjySxNy4gvJLWG1gPTXs7QQRnkS--/view
12. Panduan praktis Prolanis (Program Pengelolaan Penyakit Kronis). Badan Penyelenggara Jaminan Sosial Kesehatan. 2019. Accessed August 3, 2025. https://unitkesehatan.ipb.ac.id/wp-content/uploads/2022/07/PANDUAN-PROLANIS.pdf
13. Sulistyaningsih E. Mengenal apa itu Prolanis, beserta tujuannya? Puskesmas Sidorejo Lor. Accessed August 4, 2025. https://puskesmas-sidorejolor.salatiga.go.id/mengenal-apa-itu-prolanis-beserta-tujuannya/
14. Haris RNH, Masrida WO, Ali NFM, Fitriani RD, Irwan I, Hayati S. Gambaran kepatuhan minum obat pasien Prolanis di Puskesmas Wua-Wua. SAINTEKES. 2024;3(1):29–37. doi:10.55681/saintekes.v3i1.294
15. Prasetyo EY, Kusumaratni DA, Fatimah, Seran KE, Hariyani. Analisa hubungan karakteristik pasien terhadap kepatuhan minum obat dan kualitas hidup pasien hipertensi Prolanis di Puskesmas Sidomulyo. J Pharma Bhakta. 2023;3(2):23–30. https://www.jurnalpharmabhakta.iik.ac.id/index.php/jpb/article/view/84/44
16. Kuesioner individu survei kesehatan Indonesia 2023. Badan Kebijakan Pembangunan Kesehatan, Kementerian Kesehatan Republik Indonesia. 2023. Accessed August 10, 2025. Report V-23.0000.001. https://drive.google.com/drive/folders/1JXsXfaKSnLeEkW0WD_-Lus-tyj0JY0_a
17. Pedoman pengelolaan dan pencegahan diabetes melitus tipe 2 dewasa di Indonesia. PB PERKENI; 2023:6-99. Accessed August 18, 2025. https://pbperkeni.or.id/catalog-buku/pedoman-pengelolaan-dan-pencegahan-diabetes-melitus-tipe-2-di-indonesia-2021
18. Kristy Y, Arisandy T, Pristina N. Hubungan pengetahuan dan dukungan keluarga dengan kepatuhan kunjungan ulang peserta program rujuk balik di Klinik Induk Biddokkes Polda Kalimantan Tengah. J Ris Ilmu Kesehat Umum. 2024;2(2). doi:10.57213/jrikuf.v2i2.425
19. Firmansyah D, Dede. Teknik pengambilan sampel umum dalam metodologi penelitian: Literature review. J Ilm Pendidik Holistik. 2022;1(2):85–114. doi:10.55927/jiph.v1i2.937
20. Komariah K, Rahayu S. Hubungan usia, jenis kelamin dan indeks massa tubuh dengan kadar gula darah puasa pada pasien diabetes melitus tipe 2 di Klinik Pratama Rawat Jalan Proklamasi, Depok, Jawa Barat. J Kesehat Kusuma Husada. 2020;41–50. doi:10.34035/jk.v11i1.412
21. Sapulete IM, Sapulete MR, Ottay RI, et al. The age, smoking habits and hypertension incidence in Manado City Community: A cross-sectional study. J Bios Logos. 2025;15(1):11–8. doi: https://doi.org/10.35799/jbl.v15i1.58398
22. Riyada F, Amanah Fauziah S, Liana N, Hasni D. Faktor yang mempengaruhi terjadinya resiko hipertensi pada lansia. Sci J. 2024;3(1):27–47. doi:10.56260/sciena.v3i1.137
23. Safitri DE, Rimbawan R, Dwiriani CM, Khomsan A, Juniantito V. Risk factors of type 2 diabetes mellitus in women of reproductive age in Bekasi City. ARGIPA. 2025;9(2):139–47. doi:10.22236/argipa.v9i2.18050
24. Korompis BMK, Porajow ZCJG, Siagian IET. Prevalensi penyakit hipertensi pada masa pandemi COVID-19 di praktik dokter keluarga. J Kedokt Kom Tropik. 2022;413–6. doi: https://doi.org/10.35790/jkkt.v10i2.44878
25. Indra I, Rahmadania WO, Novianti AD, et al. The relationship between education and knowledge about diabetes mellitus in the coastal area of Lapulu District: Diabetes mellitus. Indones J Health Sci Res Dev. 2024;6(2):39–46. doi:10.36566/ijhsrd/Vol6.Iss2/241
26. Baringbing EP. Pengaruh karakteristik pendidikan dengan kejadian hipertensi pada pasien rawat jalan di RSUD dr. Doris Sylvanus Provinsi Kalimantan Tengah. J Surya Med. 2023;9(3):124–30. doi:10.33084/jsm.v9i3.6492
27. Aodina FW. Pemanfaatan program pengelolaan penyakit kronis (Prolanis) hipertensi dan diabetes melitus di Puskesmas Lawele. J Borneo Cendekia. 2023;7(1,):1–10. Accessed November 6, 2025. https://www.journal.stikesborneocendekiamedika.ac.id/index.php/jbc/article/view/336
28. Purwakanthi A, Shafira NNA, Harahap H, Kusdiyah E. Gambaran penggunaan obat diabetes mellitus pada pasien diabetes mellitus tipe 2. Jmb Med J: J Kedokt dan Kesehat. 2020;8(1):40–6. doi:10.22437/jmj.v8i1.9483
29. Panduan layanan bagi peserta jaminan kesehatan nasional kartu Indonesia sehat (JKN-KIS). Badan Penyelenggara Jaminan Sosial Kesehatan. 2024. Accessed November 7, 2025. https://web.bpjs-kesehatan.go.id/uploads/information/4bd28c6ea8f022040f6eb93cfcd6e723.pdf
30. Rista, Tjomiadi CEF, Manto OAD. Gambaran persepsi penyakit penderita DM tipe 2 di puskesmas. J Penelit Perawat Prof. 2024;6(5). doi:10.37287/jppp.v6i5.4510
31. Putri RG, Probosuseno P, Yasin NM. Narrative review: Faktor yang mempengaruhi tingkat kepatuhan terapi pada pasien diabetes melitus tipe 2. J Surya Med. 2024;10(3):309–14. doi:10.33084/jsm.v10i3.6425
32. Wahyu Hidayat A, Dyah Ayuning Putri C. Penggunaan buku sehat dan rapor Prolanis pada pasien hipertensi dan diabetes melitus tipe 2 di Puskesmas Kauman. Cerdika J Ilm Indones. 2023;3(4):394–401. doi:10.59141/cerdika.v3i4.579
33. Insani N, Nasiah N, Kholifah E. Pengaruh efek samping obat antidiabetes terhadap kualitas hidup pasien diabetes mellitus tipe 2. J Ilm Farm. 2025;14(3):252–60. doi:10.30591/pjif.v14i3.7130
34. Ismansyah. Hubungan kepatuhan kontrol dengan kadar gula darah sewaktu pada pasien DM tipe 2. Mahakam Nurs J. 2020;2(8):363–72. doi:10.35963/mnj.v2i7.18
35. Annisa M, Adam A, Ishaq Iskandar Muh, Fadli F. Analisis kepatuhan minum obat pada penderita hipertensi. Media Keperawatan Politek Kesehat Makassar. 2024;15(2):262–8. Accessed November 18, 2025. https://ojs3.poltekkes-mks.ac.id/index.php/medperawat/article/view/896
36. Haryanto E, Anshari AM, Kartikasari R. Kepatuhan minum obat hipertensi pada peserta prolanis di Puskesmas Sukawarna Kota Bandung. J Ilm JKA J Kesehat Aeromedika. 2023;9(1):44–7. doi:10.58550/jka.v9i1.197
37. Herliany YS, Bunga Laela Sary. Evaluasi kepatuhan minum obat pasien hipertensi program pengelolaan penyakit kronis(PROLANIS) di salah satu klinik Kota Bandung. Pharm Sci Clin Pharm. 2024;2(1):7–11. doi:10.61329/pscp.v2i1.26
38. Putri SR, Guna SD, Nopriadi N. Persepsi penyakit dengan tingkat kepatuhan minum obat pada pasien hipertensi di Puskesmas Rejosari. Surya Med J Ilm Ilmu Keperawatan Dan Ilmu Kesehat Masy. 2024;19(3):168–75. doi:10.32504/sm.v19i3.1199
39. Septyasari AF, Putri A, Sutaryono S, Noni M. Gambaran tingkat kepatuhan minum obat anti hipertensi pada pasien hipertensi di Desa Kujon Kecamatan Ceper Kabupaten Klaten. CERATA J Ilmu Farm. 2024;14(2):67–74. doi:10.61902/cerata.v14i2.906
40. Fahreza A, Harahap DA, Kasumayanti N. Hubungan kepatuhan minum obat anti hipertensi dengan kualitas hidup pasien hipertensi di Desa Tarai Bangun wilayah kerja Puskesmas Tambang tahun 2023. Excell Health J. 2024;3(1):572–6. doi:10.70437/excellent.v3i1.121
41. Susanto A, Purwantiningrum H, Saff MJA. Paparan informasi dan lama waktu menderita dengan kepatuhan minum obat pada penderita hipertensi. Window Health J Kesehat. 2023;6(3):227–36. doi:10.33096/woh.vi.118
42. Putri MN, Santi TD, Arbi A. Faktor-faktor yang berhubungan dengan kepatuhan kontrol berobat pasien hipertensi rawat jalan di Puskesmas Kuta Alam Kota Banda Aceh tahun 2023. J Kesehat Tambusai. 2023;4(3):3261–9. doi:10.31004/jkt.v4i3.17739
43. Panduan praktis program rujuk balik bagi peserta JKN. Badan Penyelenggara Jaminan Sosial Kesehatan. 2015.
44. Silvanasari IA, Maurida N, Vitaliati T, Basri AA. Karakteristik perilaku manajemen perawatan diri hipertensi pada lansia di Daerah Rural. Nurs Sci J. 2023;7(2):82–9. doi:10.30737/nsj.v7i2.5103
45. Puteri AMP, Nugraheni AY. Faktor yang mempengaruhi tingkat kepatuhan pengobatan pasien hipertensi di Puskesmas Kotagede II Yogyakarta. J Ilm Farm. 2023;19(2):126–42. doi:10.20885/jif.vol19.iss2.art11
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Chaerunnisa Rifai, Iyone Esra Tiurma Siagian, Margareth Rosalinda Sapulete
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
